germans trias i pujol - Fundació Institut d'Investigació en Ciències de ...

IF: 5,363
Fundació Institut d'Investigació
en Ciències de la Salut
Germans Trias i Pujol
Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, Lazzarin A, Johnson MA, Neubacher D, Mayers D,
Valdez H.
Durable efficacy of tipranavir‐ritonavir in combination with an optimised background regimen of antiretroviral
drugs for treatment‐experienced HIV‐1‐infected patients at 48 weeks in the Randomized Evaluation of Strategic
Intervention in multi‐drug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from
two randomised open‐label trials.
Lancet 2006; 368(9534):466‐75
IF: 25,8
Hill A, Walmsley S, Clotet B, Molto J.
Analysis of genotypic and phenotypic clinical cut‐off levels for ritonavir‐boosted saquinavir.
HIV Med 2006; 7(2):67‐74.
IF: 2,674
Johnson VA, Brun‐Vezinet F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD.
Update of the drug resistance mutations in HIV‐1: Fall 2006.
TOP HIV MED 2006 Aug‐Sep;14(3):125‐30
IF: 0
Law MG, Friis‐Moller N, El‐Sadr WM, Weber R, Reiss P, D'Arminio Monforte A, Thiebaut R, Morfeldt L, De Wit S,
Pradier C, Calvo G, Kirk O, Sabin CA, Phillips AN, Lundgren JD; D:A:D Study Group.
The use of the Framingham equation to predict myocardial infarctions in HIV‐infected patients: comparison with
observed events in the D:A:D Study.
HIV Med 2006 May;7(4):218‐30
IF: 2,674
Libois A, De Wit S, Poll B, Garcia F, Florence E, Del Rio A, Sanchez P, Negredo E, Vandenbruaene M, Gatell JM,
Clumeck N.
HIV and Syphilis: When to Perform a Lumbar Puncture.
SEX TRANSM DIS 2006 Jul 19;
IF: 2,577
Lifson AR, Rhame FS, Belloso WH, Dragsted UB, El‐Sadr WM, Gatell JM, Hoy JF, Krum EA, Nelson R, Pedersen C,
Pett SL, Davey RT Jr.
Reporting and evaluation of HIV‐related clinical endpoints in two multicenter international clinical trials.
HIV CLIN TRIALS 2006 May‐Jun;7(3):125‐41
IF: 1,704
Lopez JC, Moreno S, Jimenez‐Onate F, Clotet B, Rubio R, Hernandez‐Quero J.
A cohort study of the food effect on virological failure and treatment discontinuation in patients on HAART
containing didanosine enteric‐coated capsules (FOODDIe Study).
HIV CLIN TRIALS 2006; 7(4):155‐162.
IF: 1,704
Lopez S, Negredo E, Garrabou G, Puig J, Ruiz L, Sanjurjo E, Ramos X, Infante AB, Casademont J, Cardellach F, Clotet
B, Miro O.
Longitudinal study on mitochondrial effects of didanosine‐tenofovir combination.
AIDS RES HUM RETROV 2006; 22(1):33‐39.
IF: 2,513
Pàgina 54/177